Ondansetron: Uses, Dosage & Side Effects

What Is Ondansetron and What Is It Used For?

Ondansetron is a potent and selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist. Serotonin, also known as 5-HT, is a neurotransmitter that plays a central role in triggering nausea and vomiting. During cancer chemotherapy or radiation therapy, damaged cells in the gut lining release large quantities of serotonin, which stimulates the vagus nerve and the chemoreceptor trigger zone in the brainstem. By blocking the 5-HT3 receptors at these sites, ondansetron effectively interrupts the signalling cascade that leads to emesis.

First developed by GlaxoSmithKline and marketed under the brand name Zofran, ondansetron received its initial approval in the early 1990s and quickly became the gold standard for chemotherapy-induced nausea and vomiting (CINV). Today, it is manufactured by numerous pharmaceutical companies worldwide and is available as a generic medication. The World Health Organization (WHO) includes ondansetron on its Model List of Essential Medicines, underscoring its importance in global healthcare.

Ondansetron is approved for the following clinical indications:

• Chemotherapy-induced nausea and vomiting (CINV): Prevention and treatment of nausea and vomiting caused by emetogenic cancer chemotherapy in adults and children aged 6 months and older.
• Radiation-induced nausea and vomiting (RINV): Prevention and treatment of nausea and vomiting associated with radiotherapy, including total body irradiation and high-dose abdominal radiation.
• Post-operative nausea and vomiting (PONV): Prevention and treatment of nausea and vomiting following surgical procedures under general anaesthesia, in adults and children from 1 month of age.

In clinical practice, ondansetron is frequently used as part of a multimodal antiemetic regimen. For highly emetogenic chemotherapy, it is often combined with a corticosteroid (such as dexamethasone) and a neurokinin-1 (NK1) receptor antagonist (such as aprepitant) to achieve optimal protection against nausea and vomiting. Current guidelines from the American Society of Clinical Oncology (ASCO) and the Multinational Association of Supportive Care in Cancer (MASCC) recommend this triple-drug combination as first-line prophylaxis for highly emetogenic chemotherapy.

The medication is available in several formulations to suit different clinical needs. Film-coated tablets (4 mg and 8 mg) are the most common oral form for outpatient use. Orodispersible tablets dissolve on the tongue without water, which is particularly useful for patients who have difficulty swallowing or who are actively nauseated. Injectable and infusion solutions (2 mg/ml and 0.08 mg/ml) are used in hospital settings for intravenous administration when oral dosing is not feasible.

What Should You Know Before Taking Ondansetron?

Contraindications

Ondansetron must not be used if you have a known allergy or hypersensitivity to ondansetron or any of the excipients in the formulation. Cross-sensitivity may occur with other 5-HT3 receptor antagonists such as granisetron and dolasetron, so if you have had an allergic reaction to any of these medicines, inform your healthcare provider before starting ondansetron.

Warnings and Precautions

Before starting ondansetron, inform your doctor about all your medical conditions, particularly:

• Cardiac conditions: Ondansetron may prolong the QT interval on an electrocardiogram (ECG), which can potentially lead to serious cardiac arrhythmias. Patients with pre-existing heart rhythm disorders, congestive heart failure, bradycardia, or those taking other QT-prolonging medications should be monitored closely. Electrolyte imbalances, particularly low potassium (hypokalaemia) or low magnesium (hypomagnesaemia), may increase this risk and should be corrected before starting treatment.
• Bowel obstruction or severe constipation: Ondansetron may slow transit through the large intestine. If you have a complete or partial intestinal obstruction, your doctor should monitor you carefully, as the medication may mask symptoms of underlying bowel problems.
• Tonsillectomy or adenoidectomy: In patients undergoing or who have recently undergone tonsil surgery, ondansetron may mask signs of internal bleeding. Use in this context requires medical supervision.
• Hepatic impairment: Ondansetron is extensively metabolised by the liver. In patients with moderate to severe liver disease, the daily dose should not exceed 8 mg, as clearance is significantly reduced and the risk of adverse effects increases.
• Paediatric use with hepatotoxic chemotherapy: Children receiving ondansetron alongside hepatotoxic chemotherapy agents (particularly anthracyclines) should be monitored closely for signs of liver impairment.
• Electrolyte disturbances: Disorders of potassium and magnesium balance should be identified and corrected prior to ondansetron therapy, as these conditions predispose to cardiac arrhythmias.

Pregnancy and Breastfeeding

Ondansetron should not be used during the first trimester of pregnancy (first 12 weeks). Epidemiological studies have identified a small but statistically significant increased risk of orofacial cleft malformations (cleft lip and/or cleft palate) in infants exposed to ondansetron during the first trimester. The absolute risk remains low, but women of childbearing potential may be advised to use effective contraception during treatment.

Data on ondansetron use in the second and third trimesters are limited. Use during these periods should only occur when the potential benefit to the mother clearly outweighs the potential risk to the foetus. If you discover that you are pregnant while taking ondansetron, contact your healthcare provider immediately for guidance.

Ondansetron is excreted into breast milk. Women should not breastfeed during ondansetron treatment. If breastfeeding is essential, discuss alternative antiemetic options with your physician.

Driving and Operating Machinery

Ondansetron does not generally impair psychomotor performance. In clinical studies, ondansetron did not cause sedation or impair cognitive function. However, you should assess your individual response to the medication before driving or operating heavy machinery, particularly if you are receiving it in combination with other treatments that may cause drowsiness.

Excipient Information

Some formulations of ondansetron tablets contain lactose monohydrate as an excipient. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take these tablets. Consult your pharmacist or doctor if you have any of these conditions.

How Does Ondansetron Interact with Other Drugs?

Ondansetron is metabolised primarily by hepatic cytochrome P450 enzymes, particularly CYP3A4 and CYP1A2. This makes it susceptible to pharmacokinetic interactions with drugs that induce or inhibit these enzymes. Additionally, ondansetron's pharmacological effect on the QT interval necessitates careful consideration when combining it with other QT-prolonging agents.

Major Interactions

Additional Interactions

Several additional drug interactions warrant clinical consideration:

• Beta-blockers (atenolol, timolol): Used for cardiovascular conditions, anxiety, or migraine prevention. These agents may affect heart rhythm, and combined use with ondansetron may increase the risk of bradycardia or QT prolongation.
• Anthracyclines (doxorubicin, daunorubicin): These cancer chemotherapy agents are themselves cardiotoxic, and concurrent use with ondansetron may increase the risk of cardiac arrhythmias. ECG monitoring is advisable.
• Trastuzumab: Used in breast cancer treatment, trastuzumab can cause cardiac dysfunction. Combined use with ondansetron warrants cardiac monitoring.
• Erythromycin and ketoconazole: These antimicrobial agents are CYP3A4 inhibitors and may increase ondansetron plasma concentrations, potentially enhancing both its therapeutic and adverse effects, including QT prolongation.

What Is the Correct Dosage of Ondansetron?

Always take ondansetron exactly as prescribed by your doctor or pharmacist. The dosage depends on the clinical indication, the emetogenic potential of the treatment you are receiving, and your individual medical profile. Do not change your dose without consulting your healthcare provider.

Adults

Your doctor may choose to administer the first dose intravenously, especially before highly emetogenic chemotherapy. Subsequent doses are typically given orally. The initial IV dose is usually given immediately before chemotherapy begins, and oral dosing may start 12 hours later.

Children and Adolescents

Ondansetron can be used in paediatric patients under the following conditions:

• Chemotherapy-induced nausea and vomiting: Approved for children aged 6 months and older. The dose is individually calculated based on the child's body surface area (BSA). An initial intravenous dose is given immediately before chemotherapy, and oral dosing may begin 12 hours later and continue for up to 5 days. The total daily dose must not exceed 32 mg.
• Post-operative nausea and vomiting: Can be administered to children from 1 month of age, but only by slow intravenous injection. No oral dosing studies have been conducted in children for post-operative nausea, so IV administration is recommended for this indication.

Elderly Patients

Experience with ondansetron in elderly patients is more limited, but the medication is generally well tolerated in patients over 65 years of age. The same adult dosage recommendations apply for chemotherapy-induced and radiation-induced nausea. No specific dose adjustments are routinely required based on age alone, though renal and hepatic function should be taken into account, as these may decline with age.

Hepatic Impairment

In patients with moderate to severe liver impairment (Child-Pugh score B or C), the total daily dose must not exceed 8 mg. Ondansetron is extensively metabolised by the liver, and impaired hepatic function significantly reduces its clearance, leading to higher plasma concentrations and a prolonged half-life. No dose adjustment is necessary for patients with mild liver impairment.

Missed Dose

If you miss a dose of ondansetron:

• If you feel nauseated or are vomiting: Take the missed dose as soon as you remember. Then take the next dose at the usual scheduled time.
• If you are not feeling nauseated: Simply take the next dose at the regular scheduled time.
• Do not take a double dose to make up for a forgotten dose.
• Important: At least 12 hours must elapse between the last dose and the next dose.

Overdose

If too much ondansetron has been taken, or if a child has accidentally ingested the medication, seek immediate medical attention or contact your local poison control centre. Symptoms of overdose may include:

• Visual disturbances (blurred vision)
• Severe constipation
• Low blood pressure (hypotension)
• Irregular heart rhythm (cardiac arrhythmia)

There is no specific antidote for ondansetron overdose. Treatment is supportive and symptomatic, with cardiac monitoring as appropriate.

What Are the Side Effects of Ondansetron?

Like all medications, ondansetron can cause side effects, although not everyone experiences them. Most side effects are mild and resolve without treatment. However, some effects can be serious and require immediate medical attention. The following classification uses the standard medical frequency conventions based on clinical trial data and post-marketing surveillance.

Serotonin Syndrome

When ondansetron is used together with serotonergic medications (SSRIs, SNRIs, or other serotonin-active agents), there is a risk of serotonin syndrome, a potentially serious condition. Symptoms may include agitation, confusion, rapid heartbeat, high blood pressure, dilated pupils, muscle twitching, excessive sweating, and high body temperature. If you experience these symptoms, contact your doctor immediately.

Reporting Side Effects

If you experience any side effects — including those not listed here — please report them to your healthcare provider. Reporting side effects helps improve the safety information available for all medications. In the EU, you can report via your national medicines agency. In the US, side effects can be reported to the FDA MedWatch programme.

How Should You Store Ondansetron?

Proper storage of medications is essential to maintain their effectiveness and safety. Ondansetron tablets and orodispersible tablets do not generally require special storage conditions; storing them at room temperature in the original packaging is sufficient. However, some injectable formulations may have specific storage requirements — check the product labelling or consult your pharmacist.

Key storage guidelines:

• Keep all forms of ondansetron out of the sight and reach of children.
• No special temperature storage conditions are required for oral formulations.
• Do not use ondansetron after the expiry date stated on the packaging. The expiry date refers to the last day of that month.
• Do not dispose of ondansetron via wastewater or household waste. Return unused medication to your pharmacy for safe disposal to protect the environment.

What Does Ondansetron Contain?

Understanding the composition of your medication can be important, particularly if you have known allergies or intolerances to specific excipients. The exact composition may vary slightly between manufacturers, but the core ingredients are consistent across approved formulations.

Active Ingredient

Each film-coated tablet contains either 4 mg or 8 mg of ondansetron (as ondansetron hydrochloride dihydrate). The injectable solution contains 2 mg/ml of ondansetron, and the dilute infusion solution contains 0.08 mg/ml.

Inactive Ingredients (Film-Coated Tablets)

• Tablet core: Microcrystalline cellulose, lactose monohydrate, magnesium stearate, maize starch
• Film coating: Hypromellose, macrogol, titanium dioxide (E171)

Tablet Appearance

• 4 mg tablets: White, round, biconvex film-coated tablets, embossed with “4” on one side, plain on the other
• 8 mg tablets: White, round, biconvex film-coated tablets, embossed with “8” on one side, plain with a score line on the other

Available pack sizes include 5, 10, 15, 30, 50, 60, and 100 film-coated tablets in blister packs. Not all pack sizes may be marketed in every country.